tbuckley/cabot-search huggingface dataset:
Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL)
Authors: Ute E. Burkhardt, Ursula Hainz, Kristen E. Stevenson, Di Wu, Vincent T. Ho, Natalie R. Goldstein, Mildred Pasek, Jennifer R. Brown, Christine M Canning, John Koreth, Corey Cutler, Philippe Armand, Donna S. Neuberg, Joseph H. Antin, Tetsuro Sasada, Jerome Ritz, Glenn Dranoff, Robert J. Soiffer, Edwin P Alyea, Catherine J. Wu
Journal: Blood (2012)
Storage facility exists for sperm from patients positive for antibody to hepatitis C virus
Authors: E. J Massey, H Dasani, P Jones, A K N Saleem
Journal: BMJ (1996)

Storage of sperm and embryosCryopreservation of sperm should be offered to men with testicular cancer EDrroR,-Patients with testicular cancer often become infertile as a result of the disease and its treatment.It has been argued that all such patients should be offered cryopreservation of semen,' but in 1980 Braken and Smith reported that only 4% of patients had semen of suitable quality for a fertility programme.2The advent of intracytoplasmic sperm injection now allows even low quality sperm to be used successfully,3 but many clinicians are unaware of recent advances and the facilities available.To determine the awareness and availability of this service we sent a questionnaire to 292 consultant urologists, of whom 197 (67%) replied; we also contacted the 41 cryopreserva- tion centres in the United Kingdom.We found that 71 urologists routinely used cryopreservation facilities, while 123 left the oncologists to organise this.Of the 71 who routinely used the services, most (48) recommended storage of semen samples obtained after unilateral orchidectomy that was performed within one week of diagnosis; only a minority (23) thought that a short delay between diagnosis and orchidectomy would have an adverse effect on the clinical outcome.Of the 41 cryopreservation centres, only five offered storage on the NHS, but a further 10 had contracts with oncology services at preferential rates.All of the centres offered immediate access to facilities, so that the treatment of patients with cancer would not be greatly delayed.Cryopreservation of semen has been availablefor over 20 years in the United Kingdom but is still used by a minority of urologists.Infertility after the treatment of testicular cancer may be a cause of litigation, and this will become an increasingly important issue.Low cost storage of sperm is readily available in most of the United Kingdom and should be offered to patients with testicular cancer at the start of their treatment.
Genetic Variation In Recipient BAFF Modulates Phenotype of Chronic GvHD After HCT
Authors: William Clark, Dana Crawford, Brian Engelhardt, Kristin D. Brown, Fan Kang-Hsien, Heidi Chen, Bipin N. Savani, Friedrich Schuening, John P. Greer, Adetola A. Kassim, Madan Jagasia
Journal: Blood (2010)
Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group.
Authors: Eduardo M Rego, Haesook T. Kim, Guillermo J. Ruiz-Arguelles, Rosario Uriarte, Rafael H Jacomo, Homero Gutiérrez-Aguirre, Raul AM Melo, Rosane Bittencourt, Ricardo Pasquini, Katia BB Pagnano, Evandro M Fagundes, Maria LF Chauffaille de Lourdes, Carlos Chiattone, Lem Martinez, Luis A Meillon, David Gomez-Almaguer, Hau C. Kwaan, Javier Garces-Eisele, Robert E Gallagher, Charlotte M Niemeyer, Bob Lowenberg, Raul C Ribeiro, Francesco Lo-Coco, Miguel A Sanz
Journal: Blood (2009)
Impact of Persistent Antiphospholipid Antibodies on Symptomatic Thromboembolism In Children: A Systematic Review &amp; Meta-Analysis [Observational Studies]
Authors: Gili Kenet, Mariana Bonduel, Anthony Chan, Neil Goldenberg, Suzzane Holtzhauer, Alfonso Iorio, Janna M. Journeycake, Ralf Junker, Christoph Male, Mary Patricia Massicotte, Rolf M. Mesters, Paul Monagle, Heleen Van Ommen, Leslie Raffini, Paolo Simioni, Guy Young, Ulrike Nowak-Gottl
Journal: Blood (2010)
PWE-134 The Effectiveness and Patient Satisfaction of Specialist Screening Practitioner (SSP) Pre-Contact Telephone Clinic in Bowel Scope Screening
Authors: G Fitzgerald, M Mbuyongha, S Sarkar, A Gaglia, S Mumtaz-Wong
Journal: Gut (2016)

<h3>Introduction</h3> Bowel Scope is preventive intervention for colorectal cancer with a one off flexible sigmoidoscopy in the population at age 55 years. However, the invasive ‘intrusive &amp; unpleasant’ nature, the requirement of patients to self-administer their enema and that only written information is supplied as standard prior to the procedure are all likely to impact on population uptake. <h3>Aims</h3> On setting up Bowelscope at the Liverpool and Wirral Bowel Screening Centre, we trailed and then adopted a Pre-Contact SSP Telephone Clinic (PCTC) prior to Bowel scope with the aim to reassure and verbally inform patients and offer an opportunity for any questions and answers. This study was to evaluate the effectiveness of the Pre-Contact Clinic by reviewing the positive and negative impact of the clinic by reviewing the effect on patient satisfaction. <h3>Methods</h3> This study was performed from 4/15 to 12/15 at the Liverpool &amp; Wirral Bowel Screening Service and included 692 patients. <b>Trail Phase</b>: During the initial 4 month phase of roll out 1 Bowel scope list per week was performed. We trialled the PCTC by targeting alternate lists during this phase. <b>Adopted Phase:</b> following initial analysis, for the next phase- all confirmed patients were booked into a PCTC. Patient Satisfaction was measured in all patients and DNA rates monitored. <h3>Results</h3> <b>Trial Phase</b>: In the trial phase 45.7% patient were booked into PCTC with 87.9% successfully contacted. In the standard listed patients the DNA rate was 7.2%. This compared to just 3.9% in the PCTC lists. Additionally, the patient satisfaction scores for these lists were extremely high compared to the standard lists. <h3>Adopted Phase</h3> 77% capture of patients for PCTC. The DNA rate in those contacted was just 1.1% compared to 6.4% in those where pre-contact was NOT possible. In terms of patient satisfaction 98.8% of patients found PCTC useful. When rating the usefulness, the median score was 9 and mode score was 10 (scale where 1 was not at all useful &amp; 10 was extremely useful). The themed items cited were reassurance (55%), opportunity to get advice and ask questions (34%) and others (17%). An additional advantage was that although 22 patients had already chosen to not proceed but had not informed the centre or hub, due to being contacted we have had the opportunity to utilise the slots instead of them being lost to DNA. <h3>Conclusion</h3> SSP Pre-contact Telephone Clinic (PCTC) has made a significant impact on our Bowelscope service for us and particularly for the patients. As a consequence our DNA is very low and almost exclusively in the non-contacted patients. Patients are extremely satisfied with this model and it has had an impact on the uptake of Bowel scope in our centre. <h3>Disclosure of Interest</h3> None Declared
AB0987 Recurrence of Nsaid - Induced Ulcers: Has The Situation Changed in Recent Years?
Authors: A. Karateev, A. Tsurgan, N. Gontarenko
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gastric or duodenal ulcers are one of the most common side effects of NSAIDs. These lesions are important as a cause of of life-threatening complications, such as GI-bleeding. Therefore, patients who had NSAIDs-induced ulcers in history require special control for the prophylaxis of GI-complications if they need to continue to use NSAIDs. <h3>Objectives</h3> To compare the frequency of relapses of NSAIDs-induced ulcers in patients with rheumatic diseases who had long-term use of NSAIDs during the periods of 1996–2006 and 2011–2013. <h3>Methods</h3> Group 1 (1996–2006): 407 pts (85.3% females, 52.1±13.6 y.o.), with gastric or duodenal ulcers, which developed during NSAIDs treatment; and 1640 pts (83.1% females, aged 50.1±14.6 y.o.), who didn9t develop ulcer during NSAIDs intake. Group 2 (2011–2013): 82 pts (80.6% females, 58.3±12.7) with NSAIDs-induced gastric or duodenal ulcers, and 206 pts (85.1% females, 51.7±15.2 y.o.), without GI lesions during NSAIDs therapy. Patients from Group 1 used selective COX-2 inhibitors (coxibs) less in comparison to pts from Group – 4.9% vs 15.7%, as well as proton pump inhibitors (PPIs) – 14.6% vs 47.6% (<i>p</i>=0.000). All pts continued to use NSAIDs at least for one year after the first upper gastrointestinal endoscopy (UGE). All patients underwent repeated UGE after 12 months. <h3>Results</h3> Relapse of NSAID-induced ulcers were documented in 40.7% pts from Group 1, and in 28.0% pts from Group 2. Another situation was observed in patients of group 1 and 2 who did not have NSAID-induced GI lesions according data of first UGE. All of them continued to use NSAIDs ≥12 month and only 6.5% and 2.4% had developed ulcers according data of second UGE, respectively. PPI use significantly reduced the risk of relapsing NSAIDs-induced ulcers in Group 1 and 2: odds ratio (OR) 0.51 (95% CI 0.28–0.67) and OR 0.47 (95% CI 0.11–0.74). <h3>Conclusions</h3> Relapses of NSAID-induced ulcers still remain a serious problem. Pts with NSAID-induced ulcers in history should be protected with PPIs if they require continuation of using NSAIDs. Patients, who have not observed the development of NSAID-gastropathy with short-term NSAID therapy, have a lower risk of developing these lesions by continuing to use them for a long time. <h3>Disclosure of Interest</h3> None declared
THU0567 Comparative Performance of Fautrel and Yamaguchi Criteria for The Classification of Patients with Adult Onset Still Disease: Preliminary Results:
Authors: D. Lebrun, S. Mestrallet, M. Dehoux, J.-L. Golmard, S. Georgin-Lavialle, L. Arnaud, G. Grateau, J. Pouchot, B. Fautrel
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To validate Fautrel criteria set for classification of adult onset Still9s disease (AOSD), and to establish its discriminative performance to that of the Yamaguchi9s set. <h3>Methods</h3> We retrospectively reviewed the medical charts of 344 patients who had ferritin and glycosylated ferritin measured at the biochemistry laboratory of Bichat Hospital. Medical informations were extracted via a standardized form. All clinical, biological, imaging features were collected, as well as elements in favor of an alternative diagnosis, specifically symptoms suggestive of other immune-mediated inflammatory diseases (IMID) or active infections. Patients were classified as AOSD or control group, according to a predefined procedure including a review by a group of experts for difficult cases. Algorithms corresponding to Fautrel9s and Yamaguchi9s classification criteria sets were applied for each patient. <h3>Results</h3> 49 AOSD and 229 control patients were included. Fautrel9s set displayed a sensitivity of 89.8%, a specificity of 97.8%, and positive and negative predictive values of 89.8% and 97.8% respectively. 5 AOSD diagnoses were missed, and accurately classified as AOSD by standard Yamaguchi9s set. The standard Yamaguchi9s set – without strict application of exclusion criteria – produced a sensitivity of 95.9%, a specificity of 99.6%, and positive and negative predictive values of 97.9% and 99.1% respectively. 2 AOSD diagnoses were missed and correctly classified with the Fautrel9s set. If we applied a stricter definition of exclusion criteria, the sensitivity of Yamaguchi9s set decreased to 30.6% (p&lt;0.0001). 34 AOSD diagnoses were also missed. These different sets showed excellent performance, although the differences did not reach statistical significance. <h3>Conclusions</h3> Both criteria display high discrimination power in a new cohort of cases and controls. The Fautrel criteria set includes glycosylated ferritin and does not require exclusion criteria. The Yamaguchi criteria set is highly impacted by the way the satisfaction of exclusion criteria were performed. <h3>References</h3> Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still9s disease. The Journal of rheumatology. 1992;19(3):424–30. Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine. 2002;81(3):194–200. <h3>Disclosure of Interest</h3> None declared
Long-Term Outcome of Gemcitabine, Vinorelbine, Liposomal-Doxorubicin (GVD) As Salvage Regimen for Patients with Previously Heavily Treated Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma
Authors: Hui-qiang Huang, Bing Bai, Qingqing Cai, Xu-Bin Lin, Xiao-Xiao Wang, Qi-Chun Cai
Journal: Blood (2011)
Ibrutinib Plus Bendamustine/Rituximab (BR) Is Associated with Greater Reductions in Fatigue Than Placebo Plus BR Among Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Fatigue
Authors: Shana Traina, Graeme Fraser, Paula Cramer, Rodrigo Santucci Silva, Sebastian Grosicki, Marie Sarah Dilhuydy, Michelle Mahler, Mariya Salman, Angela Howes
Journal: Blood (2015)
Analysis of Long Term Outcome in Autologous Stem Cell Transplant (ASCT) for Acute Myelogenous Leukemia (AML) in First Remission (CR1) - a 15 Year Experience.
Authors: Anthony Selwyn Stein, M. O’Donnell, P. Parker, R. Spielberger, A. Nademanee, R. Bhatia, D. S. Snyder, M. Kirschbaum, V. Pullarkat, N. Kogut, E. Bolotin, K. Chang, C. Sarkodee-Adoo, M. Slovak, N. Vora, J. Land, A. Dagis, J. Palmer, S. J. Forman
Journal: Blood (2004)
THU0042 Evaluation of Synovitis at The Large Joint Using Ultrasonography and Histological Findings for RA Patients
Authors: A. Abe, H. Ishikawa, K. Wakaki, A. Murasawa
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> After starting to use biological DMARDs (bDMARD), the number of small joint (SJ) arthroplasty increased as compared with large joint (LJ) at our rheumatic center. Additionally, ultrasonography (US) for the examination of the affected joints widely utilized and it became a tool by which the rheumatologist should learn to diagnose RA and to evaluate disease activity. <h3>Objectives</h3> To clarify relationship among systemic disease activity, local disease activity using US and synovial histopathological evaluation, we examined serum CRP, MMP-3 and DAS28, and US at the surgical site before surgery. After surgery, histopathological examination of the gathered synovium at the surgical site was performed. <h3>Methods</h3> Between March, 2011 and September, 2015, 668 joints underwent surgical treatment and synovial biopsies were performed. There were 152 LJs including 8 shoulders, 60 elbows and 84 knees, and 516 SJs including185 fingers, 118 toes, 192 wrists and 21 ankles. Male: female ratio was 1:7. The bDMARD (IFX20, ETN62, ADA17, TCZ44, ABT16, CZP4, GLM13) was used in 176 cases. Maximum power Doppler (PD) signal grade of US was determined ranging from 0 to 3. They were compared with serum CRP, MMP-3, DAS28 and local disease activity using histopathological evaluation using Rooney score (RS). <h3>Results</h3> Systemic disease activity correlated with local PD signal intensity both in LJs and SJs. Also, total RS and its item score excepting "proliferating blood vessels" correlated well with PD signal intensity. Systemic disease activity, local synovial proliferation and lymphocyte infiltration were more severe in LJs than in SJs. Though sensitivity of synovitis at LJs lower than at SJs, there was not a significant difference in PD signal intensity and RS between at LJs and at SJs. RS reflected systemic disease activity more in LJs than in SJs. <h3>Conclusions</h3> US is an excellent tool to reflect local synovitis as well as systemic disease activity both in LJs and SJs. <h3>Disclosure of Interest</h3> None declared
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
Authors: Eric W F W Alton, Jeffery M Beekman, A Christopher Boyd, June Brand, Marianne S Carlon, Mary M Connolly, Mario Chan, Sinead Conlon, Heather E Davidson, Jane C Davies, Lee A Davies, Johanna F Dekkers, Ann Doherty, Sabrina Gea-Sorli, Deborah R Gill, Uta Griesenbach, Mamoru Hasegawa, Tracy E Higgins, Takashi Hironaka, Laura Hyndman, Gerry McLachlan, Makoto Inoue, Stephen C Hyde, J Alastair Innes, Toby M Maher, Caroline Moran, Cuixiang Meng, Michael C Paul-Smith, Ian A Pringle, Kamila M Pytel, Andrea Rodriguez-Martinez, Alexander C Schmidt, Barbara J Stevenson, Stephanie G Sumner-Jones, Richard Toshner, Shu Tsugumine, Marguerite W Wasowicz, Jie Zhu
Journal: Thorax (2016)

We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentiviral vectors are more efficient for lung gene transfer than non-viral vectors in preclinical models. In preparation for a first-in-man CF trial using the lentiviral vector, we have undertaken key translational preclinical studies. Regulatory-compliant vectors carrying a range of promoter/enhancer elements were assessed in mice and human air-liquid interface (ALI) cultures to select the lead candidate; cystic fibrosis transmembrane conductance receptor (CFTR) expression and function were assessed in CF models using this lead candidate vector. Toxicity was assessed and 'benchmarked' against the leading non-viral formulation recently used in a Phase IIb clinical trial. Integration site profiles were mapped and transduction efficiency determined to inform clinical trial dose-ranging. The impact of pre-existing and acquired immunity against the vector and vector stability in several clinically relevant delivery devices was assessed. A hybrid promoter hybrid cytosine guanine dinucleotide (CpG)- free CMV enhancer/elongation factor 1 alpha promoter (hCEF) consisting of the elongation factor 1α promoter and the cytomegalovirus enhancer was most efficacious in both murine lungs and human ALI cultures (both at least 2-log orders above background). The efficacy (at least 14% of airway cells transduced), toxicity and integration site profile supports further progression towards clinical trial and pre-existing and acquired immune responses do not interfere with vector efficacy. The lead rSIV.F/HN candidate expresses functional CFTR and the vector retains 90-100% transduction efficiency in clinically relevant delivery devices. The data support the progression of the F/HN-pseudotyped lentiviral vector into a first-in-man CF trial in 2017.
Core-Shell Nanostars for Multimodal Therapy and Imaging
Authors: Mengyuan Li, Lele Li, Changyou Zhan, Daniel S. Kohane
Journal: Theranostics (2016)

The coupling of diagnostic capability and effective therapy in a single multifunctional nanomedicine is desirable but remains challenging.Here, we developed multifunctional nanoparticles consisting of a gold nanostar (AuNS) core with a shell of metal-drug coordination polymer (CP).The AuNS core enabled plasmonic photothermal effect and two-photon photoluminescence (TPL), while the CP shell of gadolinium and gemcitabine monophosphate allowed chemotherapy and MRI imaging.The AuNS@CP nanoparticles exhibited a strong T 1 contrast signal and could monitor the localization of nanoparticles in vivo through noninvasive MR imaging, while intravital TPL imaging could be used to study nanoparticle behavior in tumors at the microscopic level.The combination of photothermal therapy and chemotherapy inhibited tumor growth in vivo.
Evi1 Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System
Authors: Keisuke Kataoka, Tomohiko Sato, Akihide Yoshimi, Susumu Goyama, Takako Tsuruta, Shunya Arai, Yoichi Imai, Katsuyoshi Kumagai, Naoto Kubota, Takashi Kadowaki, Mineo Kurokawa
Journal: Blood (2010)
AB0272 Anti-Rheumatic Treatment Is Not Associated with Reduction of Pentraxin 3 (PTX3) in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PSA) and Ankylosing Spondylitis (AS)
Authors: G. Deyab, I. Hokstad, S. Agewall, T. Lyberg, J.E. Whist, M.C. Smastuen, B.B. Bottazzi, G.G. Hjeltnes, P.L. Meroni, I. Hollan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> PTX3, an important component of the innate immune system,has been proposed as a useful biomarker of inflammation and cardiovascular (CV) risk, but its role in inflammatory rheumatic diseases (IRDs) is still uncertain [1,2]. <h3>Objectives</h3> The aim of this study was to examine if methotrexate (MTX) and/or anti-tumor necrosis factor treatment (anti-TNF) treatment reduced serum PTX3 (s-PTX3) levels in IRDs (RA, PsA and AS), and if s-PTX3 levels were related to other markers of inflammation and to endothelial function (EF). <h3>Methods</h3> From the biobank of PSARA, an observational study, we examined samples from 114 IRD patients starting with either MTX or anti-TNF with or without MTX (anti-TNF±MTX) due to active disease, who completed a 6 months follow up. s-PTX3 (enzyme-linked immunosorbent assay), EF (finger plethysmography) and established inflammatory biomarkers were evaluated at baseline and after 6 weeks and 6 months of therapy. <h3>Results</h3> The s-PTX3 levels in IRD and all the diagnostic subgroups were above the upper limit of the reference range. In contrast to established inflammatory markers, in particular C- reactive protein (CRP) and erythrocyte sedimentation rate (ESR) (all p-values &lt;0.05), s-PTX3 levels did not change significantly after 6 weeks and 6 months of anti-rheumatic therapy (all p&gt;0.2). The effect of MTX monotherapy and anti-TNF±MTX on s-PTX3 levels was similar. Changes in CRP, ESR and EF were not related to changes in s-PTX3 levels neither in univariate analyses nor in analyses adjusted for potential confounders. <h3>Conclusions</h3> IRD patients have increased s-PTX3 levels, which, in contrast to other inflammatory markers, do not seem to improve within 6 months of therapy with MTX and/or anti-TNF. Thus, in theory, s-PTX3 might reflect a persisting immune process, even a causal factor of the inflammation, not inhibited by the standard anti-rheumatic treatment. Furthermore, even though PTX3 is thought to be a strong predictor of CV prognosis, it was not related to EF. <h3>References</h3> Bottazzi, B., et al., An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu.Rev.Immunol., 2010. 28: p. 157–183. Jylhävä, J., et al., Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clinical and Experimental Immunology, 2011. 164(2): p. 211–217. <h3>Disclosure of Interest</h3> None declared